Search

The article reports on the activities of New York City-based Pfizer. It mentions the company's efforts in improving its Phase III clinical programs, particularly in new molecular entities (NME), treatment for rheumatoid arthritis, and its clinical trials for tanezumab. In addition, the company aims to form at least two organizations for the division of its research activities. The strategic alliances of Pfizer with other pharmaceutical companies for drug trials and development are also cited.

Information about the topics discussed during the Interphex conference which was held in New York City on March 17-19, 2009 is presented. Topics include Amgen's use of information-technology infrastructure library (ITIL) and its effectiveness in boosting productivity and cost reduction. The conference featured Jayne Morris of Amgen Inc. and Kim Van Camp of Emerson Process Management.

The article discusses the joint ventures between Bristol-Myers Squibb Co. (BMS) and Pfizer Inc. for the development and commercialization of Apixaban in New York City. Under the collaborative agreement, Pfizer will pay $250 million to BMS and will fund the development costs of the project. BMS studies the ability of the anticoagulant Apixaban in keeping and treating several venous and arterial thrombotic conditions.